Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.52 |
| ▸ | BCHE | P06276 | 2/20 | 0.52 |
| ▸ | ACHE | P22303 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | TLR2 | O60603 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.47 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL508636 | 1.00 | TSHR (0.54) | TSHRCHRM2BCHEACHEALDH1A1 | |
| SCHEMBL506861 | 0.85 | TLR2 (0.53) | ALDH1A1TLR2MEN1KMT2A | |
| SCHEMBL506862 | 0.85 | TLR2 (0.53) | ALDH1A1TLR2MEN1KMT2A | |
| SCHEMBL506094 | 0.84 | TLR2 (0.52) | CHRM2ALDH1A1TLR2 | |
| SCHEMBL506095 | 0.84 | TLR2 (0.52) | CHRM2ALDH1A1TLR2 | |
| SCHEMBL506569 | 0.81 | TLR2 (0.72) | ALDH1A1TLR2MEN1KMT2A | |
| SCHEMBL506469 | 0.81 | TLR2 (0.72) | ALDH1A1TLR2MEN1KMT2A | |
| SCHEMBL10013398 | 0.80 | ALDH1A1 (0.53) | TSHRALDH1A1NPSR1MEN1KMT2A | |
| SCHEMBL506480 | 0.80 | TLR2 (0.48) | TSHRALDH1A1TLR2MEN1KMT2A | |
| SCHEMBL506481 | 0.80 | TLR2 (0.48) | TSHRALDH1A1TLR2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853452-B2 | Compounds, their syntheses, compositions, and methods to treat cancer | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2014-10-07 | — | — | US | disclosed |
| US-20120027844-A1 | COMPOUNDS, THEIR SYNTHESES, COMPOSITIONS, AND METHODS TO TREAT CANCER | XAVIER UNIVERSITY OF LOUISIANA (US) | 2012-02-02 | — | — | US | disclosed |
| WO-2010093615-A2 | COMPOUNDS, THEIR SYNTHESES, COMPOSITIONS, AND METHODS TO TREAT CANCER | TULANE UNIVERSITY (US) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120027844-A1 | COMPOUNDS, THEIR SYNTHESES, COMPOSITIONS, AND METHODS TO TREAT CANCER | SGMS1, PHOSPHO1, MCL1 | TSHR 4652/4885CHRM2 4783/4885BCHE 1521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.